Thumbnail Image
Item

Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates

He, Linling
; 
Lin, Xiaohe
; ; 
Abraham, Ciril
; 
Sou, Cindy
; 
Ngo, Timothy
; 
Zhang, Yi
; 
Wilson, Ian A.
; 
Zhu, Jiang
Citations
Altmetric:
Genre
Journal article
Date
2021-03-19
Advisor
Committee member
Group
Fels Institute for Cancer Research and Molecular Biology (Temple University)
Department
Microbiology and Immunology
Subject
Permanent link to this record
http://hdl.handle.net/20.500.12613/7036
Collections
COVID-19 Research
Show all metadata
Files
Thumbnail Image
Wang-EtAl-JournalArticle-2021-03.pdf
Adobe PDF, 7.52 MB
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1126/sciadv.abf1591
Abstract
Vaccination against SARS-CoV-2 provides an effective tool to combat the COVID-19 pandemic. Here, we combined antigen optimization and nanoparticle display to develop vaccine candidates for SARS-CoV-2. We first displayed the receptor-binding domain (RBD) on three self-assembling protein nanoparticle (SApNP) platforms using the SpyTag/SpyCatcher system. We then identified heptad repeat 2 (HR2) in S2 as the cause of spike metastability, designed an HR2-deleted glycine-capped spike (S2GΔHR2), and displayed S2GΔHR2 on SApNPs. An antibody column specific for the RBD enabled tag-free vaccine purification. In mice, the 24-meric RBD-ferritin SApNP elicited a more potent neutralizing antibody (NAb) response than the RBD alone and the spike with two stabilizing proline mutations in S2 (S2P). S2GΔHR2 elicited twofold higher NAb titers than S2P, while S2GΔHR2 SApNPs derived from multilayered E2p and I3-01v9 60-mers elicited up to 10-fold higher NAb titers. The S2GΔHR2-presenting I3-01v9 SApNP also induced critically needed T cell immunity, thereby providing a promising vaccine candidate.
Description
Citation
L. He, X. Lin, Y. Wang, C. Abraham, C. Sou, T. Ngo, Y. Zhang, I. A. Wilson, J. Zhu, Singlecomponent, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. Sci. Adv. 7, eabf1591 (2021).
Citation to related work
American Association for the Advancement of Science
Has part
Science Advances, Vol. 7, No. 12
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
Embedded videos